Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Department of Gynaecological Oncology, Westmead Hospital, Westmead, New South Wales, Australia.
BMJ Open. 2020 Feb 27;10(2):e034579. doi: 10.1136/bmjopen-2019-034579.
Gynaecological cancers collectively account for almost 10% of cancer diagnoses made in Australian women. The extent of variation in gynaecological cancer survival rates and treatment outcomes across Australia is not well documented. The purpose of the clinical quality registry described in this paper is to systematically monitor and improve quality of care provided to these women, and facilitate clinical process improvements to ensure better patient outcomes and greater adherence to best practice care. The registry infrastructure has been developed in conjunction alongside the inaugural ovarian, tubal and peritoneal (OTP) module, allowing for concurrent piloting of the methodology and one module. Additional tumour modules will be developed in time to cover the other gynaecological tumour types.
The National Gynae-Oncology Registry (NGOR) aims to capture clinical data on all newly diagnosed cancers of the uterus, ovary, fallopian tubes, peritoneum, cervix, vulva and vagina in Australia with a view to using these data to support improved clinical care and increased adherence to 'best practice'. Data are sourced from existing clinical databases maintained by clinicians and/or hospital gynaecological cancer units. A pilot phase incorporating only OTP cancers has recently been conducted to assess the feasibility of the registry methodology and assess the support of a quality initiative of this nature among clinicians and other key stakeholders.
The NGOR has received National Mutual Acceptance (NMA) ethics approval from Monash Health Human Research Ethics Committee (HREC), NMA HREC Reference Number: HREC/17/MonH/198. We also have approval from Mercy Health HREC and University of Tasmania HREC. Data will be routinely reported back to participating sites illustrating their performance against measures of agreed best practice. It is through this feedback system that the registry will support changes to quality of care and improved patient outcomes.
妇科癌症约占澳大利亚女性癌症诊断的 10%。澳大利亚各地妇科癌症生存率和治疗结果的差异程度尚未得到充分记录。本文所述临床质量登记册的目的是系统监测和改善为这些女性提供的护理质量,并促进临床流程改进,以确保更好的患者结局和更好地遵循最佳护理实践。该登记册基础设施是与首届卵巢、输卵管和腹膜(OTP)模块一起开发的,允许同时试行该方法和一个模块。随着时间的推移,将开发更多的肿瘤模块,以涵盖其他妇科肿瘤类型。
国家妇科肿瘤登记处(NGOR)旨在收集澳大利亚所有新诊断的子宫、卵巢、输卵管、腹膜、宫颈、外阴和阴道癌症的临床数据,以期利用这些数据支持改善临床护理和增加对“最佳实践”的依从性。数据来自临床医生和/或医院妇科癌症单位维护的现有临床数据库。最近刚刚进行了一个试点阶段,仅纳入 OTP 癌症,以评估登记册方法的可行性,并评估此类质量倡议在临床医生和其他主要利益相关者中的支持程度。
NGOR 已获得莫纳什健康人类研究伦理委员会(HREC)的国家相互接受(NMA)伦理批准,NMA HREC 参考号:HREC/17/MonH/198。我们还获得了 Mercy Health HREC 和塔斯马尼亚大学 HREC 的批准。将定期向参与站点报告数据,说明他们在商定的最佳实践措施方面的表现。正是通过这个反馈系统,登记处将支持护理质量的变化和改善患者的结果。